Company news

Beyond Air, Inc. news in 2026

Beyond Air, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026

October 29, 2026

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

October 8, 2026

Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference

September 2, 2026

Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

August 31, 2026

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments

August 25, 2026

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

August 13, 2026

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026

August 4, 2026

Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

July 30, 2026

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

June 26, 2026

Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast

June 22, 2026

Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting

June 10, 2026

Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

June 1, 2026

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

April 20, 2026

Beyond Air Expands Commercial Access for LungFit PH through a Purchasing Agreement with a Top 3 National Group Purchasing Organization

April 2, 2026

Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)

March 31, 2026

Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO

March 25, 2026

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

March 17, 2026

Beyond Air to Participate in the 38th Annual Roth Conference in March

March 11, 2026

Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.

March 9, 2026

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

February 20, 2026

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

February 13, 2026

Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026

February 4, 2026

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

January 27, 2026

Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast

January 26, 2026

Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

January 14, 2026

Calls in 2026

Decks in 2026